Prostate Testing for Cancer and Treatment (ProtecT) Feasibility Study

ISRCTN ISRCTN08435261
DOI https://doi.org/10.1186/ISRCTN08435261
Secondary identifying numbers HTA 96/20/06
Submission date
20/11/2003
Registration date
20/11/2003
Last edited
26/09/2012
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Not provided at time of registration

Study website

Contact information

Prof Jenny Donovan
Scientific

Department of Social Medicine
University of Bristol
Bristol
BS8 2PR
United Kingdom

Phone +44 (0)117 928 7214
Email jenny.donovan@bristol.ac.uk

Study information

Study designMulticentre randomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeNot Specified
Participant information sheet Patient information can be found at: http://www.epi.bris.ac.uk/protect/takingpart/takingpart.htm
Scientific title
Study acronymProtecT
Study hypothesisThe overall aim was to evaluate the feasibility of a randomised controlled trial (RCT) of treatments for localised prostate cancer, including:
1. Feasibility of ‘case-finding’ in the community (including the reliability and psychosocial impact of PSA testing)
2. Determining the most efficient and effective design for a major trial of treatments
3. Randomised trial of recruitment strategies
4. Piloting outcome measures and procedures for the main trial of treatments
Ethics approval(s)Not provided at time of registration
ConditionProstate cancer
InterventionThe study was an RCT of treatment preceded by case-finding in the community, with qualitative research methods integrated at each stage. Men with confirmed localised prostate cancer were asked to consent to randomisation between a nurse or urologist for an ‘information’ appointment to discuss recruitment to the treatment trial. In the information appointment, the need for a trial was explained in detail, along with the advantages and disadvantages of each treatment, and the recruiter attempted to randomise the patient to the treatment trial or reach a patient-led preference for a treatment. All men, whether randomised or not, were asked to consent to be followed-up, and these formed a pilot for the proposed main trial.

See details of ProtecT main trial on http://www.controlled-trials.com/ISRCTN20141297
Intervention typeOther
Primary outcome measureThe primary outcome was the proportion of patients accepting randomisation to the treatment trial. Number of eligible patients randomised by nurses and urologists
Secondary outcome measuresCost effectiveness of nurses and urologists
Overall study start date01/06/1999
Overall study end date31/05/2001

Eligibility

Participant type(s)Patient
Age groupAdult
SexMale
Target number of participants150
Participant inclusion criteriaMen aged 50-69 years from specific primary care centres in the three cities were invited to attend a 30-minute prostate check clinic appointment in which they were informed about the study and asked to consent to a prostate specific antigen (PSA) test. Men with a raised PSA (initially ≥3.0 ng/ml if 50–59 years; ≥4.0 ng/ml if 60–69 years; but changed to ≥3.0 ng/ml for all men after 1 year) were invited for biopsy. Men with confirmed localised prostate cancer were invited to participate in a randomised trial of recruitment strategies.
Participant exclusion criteriaMen considered by the GP to be unfit for any of the potential treatments (ie those terminally ill or with serious co-morbidity).
Recruitment start date01/06/1999
Recruitment end date31/05/2001

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Department of Social Medicine
Bristol
BS8 2PR
United Kingdom

Sponsor information

Department of Health (UK)
Government

Quarry House
Quarry Hill
Leeds
LS2 7UE
United Kingdom

Phone +44 (0)1132 545 843
Email Sheila.Greener@doh.gsi.gov.uk
Website http://www.dh.gov.uk/en/index.htm
ROR logo "ROR" https://ror.org/03sbpja79

Funders

Funder type

Government

NIHR Health Technology Assessment Programme - HTA (UK)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 05/10/2002 Yes No
Results article results on patients' perceptions of randomisation and reasons for consent or refusal to participate in the ProtecT study 01/06/2003 Yes No
Results article results on the effectiveness of nurses and surgeons in recruiting patients 01/07/2003 Yes No
Other publications HTA monograph 01/10/2003 Yes No